Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9081)	12/30/2001 1:21:10 PM
From: dalroi	Read Replies (1) \| Respond to of 9719

V1 regarding IMCL , well i woudl sell CRXA or MOGN :-) put in a low limite of 25/28? question is , is tomorrow the time or should we wait pro tomorrow 1/ last chance for taxloss selling 2/ supposed thin market contra tomorrow 1/ if i look at the graphs of other "disasters" eg prcs uthr etc the first day isnt the lowest one can get the stock at, more like waiting 1w 2/ if osip pops tomorrow one could change part of osip for imcl 3/ i've learned not to catch a falling knife too early (i paid a heavy price for that wisom ;-( , it seems to be in all the books but most i know forget the book at those moments until they burn themselves heavily , like i did) cheers and happy new year Stefaan

To: Vector1 who wrote (9081)	12/30/2001 8:29:03 PM
From: Harold Engstrom	Respond to of 9719

From the TSC article this weekend (http://www.thestreet.com/_yahoo/tech/adamfeuerstein/10005978.html): "As Imclone shares sink because of the Erbitux delay -- no matter how long it ends up being -- investors who are losing money also are going to be reminded that Sam Waksal, his brother and company COO Harlan Waksal, as well as other Imclone executives, already have hit the best kind of jackpot -- tens of millions of dollars in cash that isn't impacted one bit by Erbitux's problems. "As part of Bristol-Myers' tender offer for 20% of Imclone, the company's executives were able to cash out a significant portion of their shares -- something first reported by TheStreet.com in September. Sam Waksal's take: approximately $36 million, according to company documents filed by the SEC. Harlan Waksal cashed out to the tune of $54 million, while company chairman Robert Goldhammer netted $25.5 million. "Ordinary investors also won because they were able to sell roughly 20% of their Imclone stake to Bristol-Myers, and at a healthy premium. But investors didn't get their Imclone shares for free, as did the Waksal brothers and other company executives -- who benefited mightily from stock purchases last summer financed with loans from the company -- at the same time they were negotiating the Bristol-Myers deal." V1, Thanks for the New Year's wishes. My family wishes yours a happy year. Hope we get to see you next time you fly in. H